title: P2 receptor-mediated proliferative effects on astrocytes in vivo.
abstract: Astrogliosis in response to injury usually represents up-regulation of glial fibrillary acidic protein (GFAP), hypertrophy, and proliferation. Following pathological events in brain tissue, purine nucleotides and nucleosides are released into the extracellular space. The (patho)physiological importance and molecular mechanisms of the purinoceptor-mediated effects are nearly unknown. In the present study, the involvement of extracellular ATP in astrogliotic processes via stimulation of P2 receptors was investigated. The structural analogue, 2-methylthio ATP (2-MeSATP) and its antagonists reactive blue 2 and pyridoxal-phosphate-6-azophenyl-2,4-disulphonic acid (PPADS) were microinfused in situ into the rat nucleus accumbens. The reaction of astrocytes in the nucleus accumbens was investigated by GFAP- and 5-bromo-2'-deoxyuridine (BrdU)- immunocytochemistry. Tissue injury due to the microinjection procedure caused astrogliosis, which was increased further by 2-MeSATP. Up-regulation of GFAP-immunoreactivity, hypertrophy of astrocytes, and an increase in the number of GFAP-positive and of GFAP-/BrdU-double labeled cells were observed. Reactive blue 2 and PPADS decreased the consequences of tissue injury on astrocytic proliferation when given alone. In addition, both antagonists counteracted the 2-MeSATP-induced astrogliosis, supporting the hypothesis that purine nucleotides are involved in these processes via stimulation of P2 receptors in vivo.
authors.affiliation: Department of Pharmacology and Toxicology, University of Leipzig, Leipzig, Germany. frah@medizin.uni-leipzig.de
authors.forename: H
authors.initials: H
authors.lastname: Franke
authors.forename: U
authors.initials: U
authors.lastname: Krügel
authors.forename: P
authors.initials: P
authors.lastname: Illes
mesh_terms: D000255:Adenosine Triphosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D001253:Astrocytes / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D002455:Cell Division / Q000187:drug effects / Q000502:physiology; D004347:Drug Interactions; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D005911:Gliosis / Q000209:etiology / Q000473:pathology; D008297:Male; D008845:Microinjections / Q000009:adverse effects; D058919:Purinergic P2 Receptor Antagonists; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D018048:Receptors, Purinergic P2 / Q000502:physiology*; D013873:Thionucleotides / Q000494:pharmacology; D014227:Triazines / Q000494:pharmacology
chemical_list: D005904:Glial Fibrillary Acidic Protein; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2; D013873:Thionucleotides; D014227:Triazines; C077792:pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid; C012842:Cibacron Blue F 3GA; D011732:Pyridoxal Phosphate; D000255:Adenosine Triphosphate; C008501:2-methylthio-ATP